Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

Researchers identify new major cause of inflammatory bowel disease

Crohn’s disease and ulcerative colitis affected more than 500,000 people in the UK in 2022

- PMLiVE

Roche’s ALK inhibitor Alecensa granted EC approval to treat early-stage lung cancer

Non-small cell lung cancer represents up to 85% of all lung cancer diagnoses

- PMLiVE

GSK’s RSV vaccine Arexvy approved by FDA for use in adults aged 50 to 59 years

The decision comes just over a year after the FDA approved Arexvy for use in adults aged 60 years and older

- PMLiVE

Tiziana shares promising results for intranasal foralumab in secondary progressive MS

The neurological disease is estimated to affect 2.8 million people globally

- PMLiVE

Mental health in the workplace – the vital role of good people management

By Rebecca Hall

- PMLiVE

Engaging with HCPs – are you optimising your remote and in-person communications?

By Lorraine Walters

- PMLiVE

FDA approves Geron’s Rytelo to treat lower-risk myelodysplastic syndrome patients

The oligonucleotide telomerase inhibitor is administered as an intravenous infusion every four weeks

- PMLiVE

BMS shares positive phase 3 results for Opdivo/Yervoy combination in liver cancer

Hepatocellular carcinoma accounts for 90% of all liver cancer cases and is often diagnosed at an advanced stage

- PMLiVE

GSK enhances oligonucleotide capabilities with $50m Elsie acquisition

The ability of oligonucleotides to modulate gene expression makes them an attractive modality for drugmakers

- PMLiVE

PM Society Digital Awards – tickets now on sale!

The ceremony will take place on 12 September 2024 at The Brewery in London

- PMLiVE

The increasing impact of AI on healthcare

By Abi Drabble

- PMLiVE

Creativity in healthcare: think like a child before acting like an adult

By Rebecca Fergusson

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links